Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of β-catenin/E-cadherin signaling

Molecular and Cellular Endocrinology

Volumn 366, Issue 1, 2013, Pages 90-98

  Cho, Sun Wook ^a   Lee, Eun Jung ^a   Kim, HwanHee ^a   Kim, Soon Hui ^a   Ahn, Hwa Young ^a,d   Kim, Young A ^a   Yi, Ka Hee ^c   Park, Do Joon ^a   Shin, Chan Soo ^a   Ahn, Soon Hyun ^a   Cho, Bo Youn ^a,d   Park, Young Joo ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

Catenin; Dkk 1; E cadherin; Papillary thyroid cancer; Wnt

Indexed keywords

BETA CATENIN; BROXURIDINE; DICKKOPF 1 PROTEIN; MESSENGER RNA; RECOMBINANT DICKKOPF 1 PROTEIN; RECOMBINANT PROTEIN; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA;

APOPTOSIS; BETA CATENIN; CADHERINS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84872492600     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.12.007     Document Type: Article

References (55)

1. Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S.A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 2001, 3:683-686.
2. Bafico A., Liu G., Goldin L., Harris V., Aaronson S.A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004, 6:497-506.
3. Barker N., Clevers H. Catenins, Wnt signaling and cancer. Bioessays 2000, 22:961-965.
4. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
5. Bohm J., Niskanen L., Kiraly K., Kellokoski J., Eskelinen M., Hollmen S., Alhava E., Kosma V.M. Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2000, 85:4806-4811.
6. Bonvini P., An W.G., Rosolen A., Nguyen P., Trepel J., Garcia de Herreros A., Dunach M., Neckers L.M. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res. 2001, 61:1671-1677.
7. Brabant G., Hoang-Vu C., Cetin Y., Dralle H., Scheumann G., Molne J., Hansson G., Jansson S., Ericson L.E., Nilsson M. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 1993, 53:4987-4993.
8. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
9. Cassinelli G., Favini E., Degl'Innocenti D., Salvi A., De Petro G., Pierotti M.A., Zunino F., Borrello M.G., Lanzi C. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 2009, 11:10-21.
10. Castellone M.D., De Falco V., Rao D.M., Bellelli R., Muthu M., Basolo F., Fusco A., Gutkind J.S., Santoro M. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 2009, 69:1867-1876.
11. Ciruna B., Rossant J. FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev. Cell 2001, 1:37-49.
12. Civitareale D., Lonigro R., Sinclair A.J., Di Lauro R. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989, 8:2537-2542.
13. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
14. Conacci-Sorrell M., Zhurinsky J., Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 2002, 109:987-991.
15. Fedi P., Bafico A., Nieto Soria A., Burgess W.H., Miki T., Bottaro D.P., Kraus M.H., Aaronson S.A. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 1999, 274:19465-19472.
16. Garcia-Rostan G., Tallini G., Herrero A., D'Aquila T.G., Carcangiu M.L., Rimm D.L. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999, 59:1811-1815.
17. Garcia-Rostan G., Camp R.L., Herrero A., Carcangiu M.L., Rimm D.L., Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 2001, 158:987-996.
18. Gat U., DasGupta R., Degenstein L., Fuchs E. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998, 95:605-614.
19. Gilbert-Sirieix M., Makoukji J., Kimura S., Talbot M., Caillou B., Massaad C., Massaad-Massade L. Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells. PLoS ONE 2011, 6:e22280.
20. Hahn J.Y., Cho H.J., Bae J.W., Yuk H.S., Kim K.I., Park K.W., Koo B.K., Chae I.H., Shin C.S., Oh B.H., Choi Y.S., Park Y.B., Kim H.S. Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts. J. Biol. Chem. 2006, 281:30979-30989.
21. Ishigaki K., Namba H., Nakashima M., Nakayama T., Mitsutake N., Hayashi T., Maeda S., Ichinose M., Kanematsu T., Yamashita S. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J. Clin. Endocrinol. Meta. 2002, 87:3433-3440.
22. Itoh K., Krupnik V.E., Sokol S.Y. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr. Biol. 1998, 8:591-594.
23. Jiang T., Wang S., Huang L., Zhang S. Clinical significance of serum DKK-1 in patients with gynecological cancer. Int. J. Gynecol. Cancer 2009, 19:1177-1181.
24. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63:1454-1457.
25. Koh C.S., Ku J.L., Park S.Y., Kim K.H., Choi J.S., Kim I.J., Park J.H., Oh S.K., Chung J.K., Lee J.H., Kim W.H., Kim C.W., Cho B.Y., Park J.G. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol. Cell. Endocrinol. 2007, 264:118-127.
26. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
27. Kuphal S., Lodermeyer S., Bataille F., Schuierer M., Hoang B.H., Bosserhoff A.K. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene 2006, 25:5027-5036.
28. Kurihara T., Ikeda S., Ishizaki Y., Fujimori M., Tokumoto N., Hirata Y., Ozaki S., Okajima M., Sugino K., Asahara T. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004, 14:1020-1029.
29. Le T.L., Yap A.S., Stow J.L. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J. Cell. Biol. 1999, 146:219-232.
30. Lee A.Y., He B., You L., Xu Z., Mazieres J., Reguart N., Mikami I., Batra S., Jablons D.M. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem. Biophys. Res. Commun. 2004, 323:1246-1250.
31. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
32. Mikheev A.M., Mikheeva S.A., Liu B., Cohen P., Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 2004, 25:47-59.
33. Mikheev A.M., Mikheeva S.A., Rostomily R., Zarbl H. Dickkopf-1 activates cell death in MDA-MB435 melanoma cells. Biochem. Biophys. Res. Commun. 2007, 352:675-680.
34. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
35. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
36. Ordonez N.G. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv. Anat. Pathol. 2000, 7:123-127.
37. Park Y.J., Kim T.Y., Lee S.H., Kim H., Kim S.W., Shong M., Yoon Y.K., Cho B.Y., Park D.J. P66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling. Endocrinology 2005, 146:2473-2480.
38. Park Y.J., Lee Y.J., Kim S.H., Joung D.S., Kim B.J., So I., Park do J., Cho B.Y. Ghrelin enhances the proliferating effect of thyroid stimulating hormone in FRTL-5 thyroid cells. Mol. Cell. Endocrinol. 2008, 285:19-25.
39. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000, 287:1606-1609.
40. Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N., Garcia de Herreros A., Dunach M. P120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol. Cell. Biol. 2003, 23:2287-2297.
41. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
42. Polakis P. More than one way to skin a catenin. Cell 2001, 105:563-566.
43. Qin X., Zhang H., Zhou X., Wang C., Zhang X., Ye L. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl. Res. 2007, 150:281-294.
44. Roura S., Miravet S., Piedra J., Garcia de Herreros A., Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J. Biol. Chem. 1999, 274:36734-36740.
45. Sastre-Perona A., Santisteban P. Role of the wnt pathway in thyroid cancer. Front. Endocrinol. (Lausanne) 2012, 3:31.
46. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., Murata M., Shimano T., Yamaoka Y., Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 2000, 24:245-250.
47. Scheumman G.F., Hoang-Vu C., Cetin Y., Gimm O., Behrends J., von Wasielewski R., Georgii A., Birchmeier W., von Zur Muhlen A., Dralle H., et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J. Clin. Endocrinol. Metab. 1995, 80:2168-2172.
48. Shou J., Ali-Osman F., Multani A.S., Pathak S., Fedi P., Srivenugopal K.S. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 2002, 21:878-889.
49. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho T., Seruca R., Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
50. Takahashi N., Fukushima T., Yorita K., Tanaka H., Chijiiwa K., Kataoka H. Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth. Int. J. Cancer. 2010, 126:1611-1620.
51. Tartari C.J., Donadoni C., Manieri E., Mologni L., Mina P.D., Villa A., Gambacorti-Passerini C. Dissection of the RET/beta-catenin interaction in the TPC1 thyroid cancer cell line. Am. J. Cancer Res. 2011, 1:716-725.
52. Tsuda M., Kamimura K., Nakato H., Archer M., Staatz W., Fox B., Humphrey M., Olson S., Futch T., Kaluza V., Siegfried E., Stam L., Selleck S.B. The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila. Nature 1999, 400:276-280.
53. Veliz J., Brantes S., Ramos C., Aguayo J., Caceres E., Herrera M., Barber A., Barria M., Wohllk N. Thyroglobulin levels in needle lymph node cytology for the detection of papillary thyroid cancer recurrence. Rev. Med. Chile. 2008, 136:1107-1112.
54. von Wasielewski R., Rhein A., Werner M., Scheumann G.F., Dralle H., Potter E., Brabant G., Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res. 1997, 57:2501-2507.
55. Yamabuki T., Takano A., Hayama S., Ishikawa N., Kato T., Miyamoto M., Ito T., Ito H., Miyagi Y., Nakayama H., Fujita M., Hosokawa M., Tsuchiya E., Kohno N., Kondo S., Nakamura Y., Daigo Y. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007, 67:2517-2525.